Should hydrocortisone be prescribed for acute sinusitis in an otherwise healthy adult?

Do Not Give Hydrocortisone (Systemic Corticosteroids) for Routine Acute Sinusitis

Systemic corticosteroids, including hydrocortisone, should NOT be used routinely for acute bacterial rhinosinusitis (ABRS) in otherwise healthy adults. The evidence shows limited benefit with potential for adverse effects, and current guidelines do not support their routine use.

Evidence-Based Reasoning

Primary Guideline Recommendations

The most recent and authoritative guideline (2025) from the American Academy of Otolaryngology explicitly addresses this question 1. Multiple established guidelines consistently recommend against routine systemic corticosteroid use for uncomplicated acute sinusitis [@1,2,3@]23.

Intranasal corticosteroids are recommended as adjunctive therapy, not systemic steroids 24. The 2012 IDSA guideline specifically states that intranasal corticosteroids (not oral/systemic) should be used as an adjunct to antibiotics, primarily in patients with allergic rhinitis 2.

When Systemic Steroids Might Be Considered (Limited Circumstances)

The 2005 guideline provides the most specific guidance: "The short-term use of oral corticosteroids as an adjunct in treating patients with acute sinusitis is reasonable when the patient fails to respond to initial treatment, demonstrates nasal polyposis, or has demonstrated marked mucosal edema" [@1,2,3@]. This is NOT first-line therapy but rather a salvage option.

Key criteria for considering systemic steroids:

• Treatment failure after initial antibiotic therapy (3-5 days without improvement)
• Nasal polyposis present
• Marked mucosal edema documented

Evidence Quality and Outcomes

The Cochrane systematic review found that oral corticosteroids combined with antibiotics showed only modest short-term benefit (number needed to treat = 7) for symptom relief at 3-7 days 5. However:

• No benefit as monotherapy (without antibiotics) 5
• Benefits were not sustained at 10 weeks follow-up 6
• Significant risk of attrition bias in the studies 5
• Most studies were in secondary care settings, not primary care 5

The European Position Paper (2020) explicitly advises against systemic corticosteroids for post-viral rhinosinusitis, noting no positive effect on recovery at 7-14 days and only small effects on facial pain at days 4-7 7.

Adverse Effects Profile

Even short courses carry risks:

• Gastrointestinal disturbances (RR 3.45) 6
• Insomnia (RR 3.63) 6
• Potential mood disturbances 6
• Nausea, vomiting, gastric complaints 5

Recommended Treatment Algorithm

First-Line Management (Days 0-5)

1. Watchful waiting for uncomplicated ABRS regardless of severity 14
2. Symptomatic relief: analgesics, saline irrigation, adequate hydration [@1,2,3@]
3. Intranasal corticosteroids (not systemic) as adjunct 24

If Antibiotics Are Indicated

• Start amoxicillin with or without clavulanate 23
• Duration: 5-7 days in adults, 10-14 days in children 2

Treatment Failure (After 3-5 Days)

• Switch to alternative antibiotic [@1,2,3@]2
• Consider short-course oral corticosteroids ONLY if:
  • Nasal polyps present
  • Marked mucosal edema documented
  • Severe symptoms persisting despite appropriate antibiotics

Dosing If Systemic Steroids Are Used

The FDA label for hydrocortisone indicates dosing of 20-240 mg/day depending on disease severity 8, but prednisone is more commonly used in practice (typical dose: 40-60 mg daily for 5-7 days based on survey data) 9.

Critical Pitfalls to Avoid

1. Do not use systemic steroids as first-line therapy for uncomplicated acute sinusitis
2. Do not confuse intranasal with systemic corticosteroids - intranasal is recommended, systemic is not 24
3. Do not prescribe for chronic rhinosinusitis - no evidence supports routine empiric use 10
4. Do not use as monotherapy - if used at all, must be combined with antibiotics 5

Special Populations

• Chronic rhinosinusitis: Systemic steroids are NOT recommended for routine empiric use 10
• Children: Even less evidence; intranasal steroids preferred 11
• Immunocompromised or complicated cases: Refer to specialist 2

Bottom line: Reserve intranasal corticosteroids for adjunctive therapy in ABRS, and only consider short-course systemic corticosteroids in treatment-refractory cases with specific features (polyps, marked edema) after initial antibiotic failure.